Exelixis (EXEL) Cost of Revenue (2013 - 2026)
Exelixis (EXEL) posted quarterly Cost of Revenue of $20.0 million for Q2 2026, up 4.07% year-over-year from $19.2 million in Q2 2025, and down 24.65% quarter-over-quarter from $26.5 million in Q1 2026.
Analysis
Exelixis (EXEL) Cost of Revenue (2013 - 2026) Analysis & Trends
Exelixis' Cost of Revenue history runs 14 years deep, the most recent figure standing at $20.0 million for Q2 2026.
- In Q2 2026, Cost of Revenue rose 4.07% year-over-year to $20.0 million; the TTM figure through Apr 2026 stood at $84.5 million (up 13.96% YoY), while the FY2026 annual figure was $83.7 million, up 9.82% from the prior year.
- Cost of Revenue for Q2 2026 stood at $20.0 million, down from $26.5 million in the prior quarter.
- The five-year high for Cost of Revenue was $26.5 million in Q1 2026, with the low at $13.2 million in Q2 2022.
- The 5-year median for Cost of Revenue is $18.6 million (2025), against an average of $18.3 million.
- The sharpest annual moves came in 2024 and 2025: Cost of Revenue jumped 48.49% in 2024, then slipped 9.8% in 2025.
- Exelixis' Cost of Revenue stood at $15.9 million in 2022, then jumped by 36.64% to $21.8 million in 2023, then dropped by 20.34% to $17.3 million in 2024, then advanced by 7.19% to $18.6 million in 2025, then climbed by 7.42% to $20.0 million in 2026.
- Business Quant data shows EXEL's Cost of Revenue at $20.0 million in Q2 2026, $26.5 million in Q1 2026, and $18.6 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 93.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 174.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 298.26 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn | 20.66 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 20.66 Mn |
| Apr 3, 2026 | 19.95 Mn |
| Jan 2, 2026 | 26.48 Mn |
| Oct 3, 2025 | 18.57 Mn |
| Jul 4, 2025 | 19.47 Mn |
| Apr 4, 2025 | 19.17 Mn |
| Jan 3, 2025 | 19.97 Mn |
| Sep 27, 2024 | 17.33 Mn |
| Jun 28, 2024 | 17.67 Mn |
| Mar 29, 2024 | 21.26 Mn |
| Dec 29, 2023 | 21.75 Mn |
| Sep 29, 2023 | 18.77 Mn |
| Jun 30, 2023 | 17.71 Mn |
| Mar 31, 2023 | 14.32 Mn |
| Dec 30, 2022 | 15.92 Mn |
| Sep 30, 2022 | 15.31 Mn |
| Jul 1, 2022 | 13.48 Mn |
| Apr 1, 2022 | 13.20 Mn |
| Dec 31, 2021 | 12.92 Mn |
| Oct 1, 2021 | 11.87 Mn |